D. Boral Capital Reiterates Buy Rating for Can-Fite BioPharma (NYSE:CANF)
Can-Fite BioPharma (NYSE:CANF – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock. Several other research firms have also recently issued reports on CANF. StockNews.com started coverage on shares of […]
Can-Fite BioPharma (NYSE:CANF – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock. Several other research firms have also recently issued reports on CANF. StockNews.com started coverage on shares of […]
